The anxiolytic buspirone shifts coping strategy in novel environmental context of mice with different anxious phenotype

Behavioural Brain Research

Volumn 250, Issue , 2013, Pages 32-38

  Horváth, János ^a   Szögi, Titanilla ^a   Müller, Géza ^a   Szegedi, Viktor ^b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b INSTITUTE OF BIOCHEMISTRY   (Hungary)

Author keywords

Anxiety; AX; Context change; Elevated plus maze; Inbred mice; NAX

Indexed keywords

BUSPIRONE;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; BEHAVIORAL SCIENCE; CONTROLLED STUDY; COPING BEHAVIOR; DOSE RESPONSE; DRUG EFFECT; EXPLORATORY BEHAVIOR; MALE; MAZE TEST; MOTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOCIAL ENVIRONMENT; STRAIN DIFFERENCE;

ADAPTATION, PSYCHOLOGICAL; ANALYSIS OF VARIANCE; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BUSPIRONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENVIRONMENT; EXPLORATORY BEHAVIOR; MAZE LEARNING; MICE; TIME FACTORS;

EID: 84878421149     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.04.014     Document Type: Article

References (31)

1. Borsini F., Brambilla A., Grippa N., Pitsikas N. Behavioral effects of flibanserin (BIMT 17). Pharmacology, Biochemistry, and Behavior 1999, 64(1):137-146.
2. Bouwknecht J.A., van der Gugten J., Groenink L., Olivier B., Paylor R.E. Behavioral and physiological mouse models for anxiety: effects of flesinoxan in 129S6/SvEvTac and C57BL/6J mice. European Journal of Pharmacology 2004, 494(1):45-53.
3. File S.E., Zangrossi H. "One-trial tolerance" to the anxiolytic actions of benzodiazepines in the elevated plus-maze, or the development of a phobic state?. Psychopharmacology 1993, 110(1-2):240-244.
4. File S.E., Zangrossi H., Sanders F.L., Mabbutt P.S. Raised corticosterone in the rat after exposure to the elevated plus-maze. Psychopharmacology 1994, 113(3-4):543-546.
5. File S.E., Zangrossi H., Viana M., Graeff F.G. Trial 2 in the elevated plus-maze: a different form of fear?. Psychopharmacology 1993, 111(4):491-494.
6. Frussa-Filho R., Ribeiro Rde A. One-trial tolerance to the effects of chlordiazepoxide in the elevated plus-maze is not due to acquisition of a phobic avoidance of open arms during initial exposure. Life Sciences 2002, 71(5):519-525.
7. Griebel G., Misslin R., Pawlowski M., Guardiola Lemaitre B., Guillaumet G., Bizot-Espiard J. Anxiolytic-like effects of a selective 5-HT1A agonist, S20244, and its enantiomers in mice. Neuroreport 1992, 3(1):84-86.
8. Haller J., Alicki M. Current animal models of anxiety, anxiety disorders, and anxiolytic drugs. Current Opinion in Psychiatry 2012, 25(1):59-64.
9. Hillegaart V., Estival A., Ahlenius S. Evidence for specific involvement of 5-HT1A and 5-HT2A/C receptors in the expression of patterns of spontaneous motor activity of the rat. European Journal of Pharmacology 1996, 295(2-3):155-161.
10. Hjorth S. Serotonin 5-HT1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: a microdialysis study. Journal of Neurochemistry 1993, 60(2):776-779.
11. Hjorth S., Bengtsson H.J., Kullberg A., Carlzon D., Peilot H., Auerbach S.B. Serotonin autoreceptor function and antidepressant drug action. Journal of Psychopharmacology (Oxford, England) 2000, 14(2):177-185.
12. Holmes A., Parmigiani S., Ferrari P.F., Palanza P., Rodgers R.J. Behavioral profile of wild mice in the elevated plus-maze test for anxiety. Physiology & Behavior 2000, 71(5):509-516.
13. Hurst J.L., West R.S. Taming anxiety in laboratory mice. Nature Methods 2010, 7(10):825-826.
14. Keck M.E., Welt T., Post A., Muller M.B., Toschi N., Wigger A., et al. Neuroendocrine and behavioral effects of repetitive transcranial magnetic stimulation in a psychopathological animal model are suggestive of antidepressant-like effects. Neuropsychopharmacology 2001, 24(4):337-349.
15. Keck M.E., Wigger A., Welt T., Muller M.B., Gesing A., Reul J.M., et al. Vasopressin mediates the response of the combined dexamethasone/CRH test in hyper-anxious rats: implications for pathogenesis of affective disorders. Neuropsychopharmacology 2002, 26(1):94-105.
16. Kessler R.C., Chiu W.T., Demler O., Merikangas K.R., Walters E.E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry 2005, 62(6):617-627.
17. Kostowski W., Plaznik A., Stefanski R. Intra-hippocampal buspirone in animal models of anxiety. European Journal of Pharmacology 1989, 168(3):393-396.
18. Lee C., Rodgers R.J. Antinociceptive effects of elevated plus-maze exposure: influence of opiate receptor manipulations. Psychopharmacology 1990, 102(4):507-513.
19. Misslin R., Griebel G., Saffroy-Spittler M., Vogel E. Anxiolytic and sedative effects of 5-HT1A ligands, 8-OH-DPAT and MDL 73005EF, in mice. Neuroreport 1990, 1(3-4):267-270.
20. Ohl F., Toschi N., Wigger A., Henniger M.S., Landgraf R. Dimensions of emotionality in a rat model of innate anxiety. Behavioral Neuroscience 2001, 115(2):429-436.
21. Pawlak C.R., Ho Y.J., Schwarting R.K. Animal models of human psychopathology based on individual differences in novelty-seeking and anxiety. Neuroscience and Biobehavioral Reviews 2008, 32(8):1544-1568.
22. Pereira J.K., Vieira R.J., Konishi C.T., Ribeiro R.A., Frussa-Filho R. The phenomenon of "one-trial tolerance" to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze is abolished by the introduction of a motivational conflict situation. Life Sciences 1999, 65(10):PL101-PL107.
23. Pineyro G., Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacological Reviews 1999, 51(3):533-591.
24. Rodgers R.J., Johnson N.J., Carr J., Hodgson T.P. Resistance of experientially-induced changes in murine plus-maze behaviour to altered retest conditions. Behavioural Brain Research 1997, 86(1):71-77.
25. Rodgers R.J., Lee C., Shepherd J.K. Effects of diazepam on behavioural and antinociceptive responses to the elevated plus-maze in male mice depend upon treatment regimen and prior maze experience. Psychopharmacology 1992, 106(1):102-110.
26. Rodgers R.J., Shepherd J.K. Influence of prior maze experience on behaviour and response to diazepam in the elevated plus-maze and light/dark tests of anxiety in mice. Psychopharmacology 1993, 113(2):237-242.
27. Stefanski R., Palejko W., Bidzinski A., Kostowski W., Plaznik A. Serotonergic innervation of the hippocampus and nucleus accumbens septi and the anxiolytic-like action of midazolam and 5-HT1A receptor agonists. Neuropharmacology 1993, 32(10):977-985.
28. Szego E.M., Janaky T., Szabo Z., Csorba A., Kompagne H., Muller G., et al. A mouse model of anxiety molecularly characterized by altered protein networks in the brain proteome. European Neuropsychopharmacology 2010, 20(2):96-111.
29. Thiel C.M., Muller C.P., Huston J.P., Schwarting R.K. High versus low reactivity to a novel environment: behavioural, pharmacological and neurochemical assessments. Neuroscience 1999, 93(1):243-251.
30. Trullas R., Skolnick P. Differences in fear motivated behaviors among inbred mouse strains. Psychopharmacology 1993, 111(3):323-331.
31. Virok D.P., Kis Z., Szegedi V., Juhasz G., Zvara A., Muller G., et al. Functional changes in transcriptomes of the prefrontal cortex and hippocampus in a mouse model of anxiety. Pharmacological Report 2011, 63(2):348-361.